ATE336575T1 - Die interaktion von beta-catenin, tcf-4 und apc führt zur verhütung von krebs - Google Patents
Die interaktion von beta-catenin, tcf-4 und apc führt zur verhütung von krebsInfo
- Publication number
- ATE336575T1 ATE336575T1 AT98912994T AT98912994T ATE336575T1 AT E336575 T1 ATE336575 T1 AT E336575T1 AT 98912994 T AT98912994 T AT 98912994T AT 98912994 T AT98912994 T AT 98912994T AT E336575 T1 ATE336575 T1 AT E336575T1
- Authority
- AT
- Austria
- Prior art keywords
- catenin
- beta
- apc
- tcf
- transcription
- Prior art date
Links
- 102000015735 Beta-catenin Human genes 0.000 title abstract 8
- 108060000903 Beta-catenin Proteins 0.000 title abstract 8
- 206010028980 Neoplasm Diseases 0.000 title 1
- 108010048992 Transcription Factor 4 Proteins 0.000 title 1
- 102000009523 Transcription Factor 4 Human genes 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000003993 interaction Effects 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 abstract 5
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 230000035897 transcription Effects 0.000 abstract 3
- 238000013518 transcription Methods 0.000 abstract 3
- 108700001666 APC Genes Proteins 0.000 abstract 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 2
- 102000000479 TCF Transcription Factors Human genes 0.000 abstract 2
- 108010016283 TCF Transcription Factors Proteins 0.000 abstract 2
- 230000033228 biological regulation Effects 0.000 abstract 2
- 230000000112 colonic effect Effects 0.000 abstract 2
- 210000000981 epithelium Anatomy 0.000 abstract 2
- 230000035772 mutation Effects 0.000 abstract 2
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 108700008625 Reporter Genes Proteins 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 230000026731 phosphorylation Effects 0.000 abstract 1
- 238000006366 phosphorylation reaction Methods 0.000 abstract 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000009466 transformation Effects 0.000 abstract 1
- 230000002100 tumorsuppressive effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Inorganic Compounds Of Heavy Metals (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/821,355 US5851775A (en) | 1997-03-20 | 1997-03-20 | β-catenin, Tcf-4, and APC interact to prevent cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE336575T1 true ATE336575T1 (de) | 2006-09-15 |
Family
ID=25233161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98912994T ATE336575T1 (de) | 1997-03-20 | 1998-03-20 | Die interaktion von beta-catenin, tcf-4 und apc führt zur verhütung von krebs |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US5851775A (de) |
| EP (1) | EP0972037B1 (de) |
| JP (1) | JP2001522234A (de) |
| AT (1) | ATE336575T1 (de) |
| AU (1) | AU6765898A (de) |
| CA (1) | CA2285701C (de) |
| DE (1) | DE69835590T2 (de) |
| WO (1) | WO1998041631A2 (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6140052A (en) * | 1997-03-20 | 2000-10-31 | The Johns Hopkins University | cMYC is regulated by Tcf-4 |
| WO1999042481A2 (de) * | 1998-02-21 | 1999-08-26 | Max-Delbrück-Centrum für Molekulare Medizin | MITTEL ZUR THERAPIE VON MENSCHLICHEN ERKRANKUNGEN, AUSGEHEND VON β-CATENIN, SEINE HERSTELLUNG UND SEINE VERWENDUNG |
| WO2000018913A1 (en) * | 1998-09-25 | 2000-04-06 | Universiteit Utrecht | Apc-2 |
| GB9906815D0 (en) | 1999-03-24 | 1999-05-19 | Isrec | Anti-neoplastic viral agents |
| AU4314100A (en) * | 1999-04-27 | 2000-11-10 | Kyowa Hakko Kogyo Co. Ltd. | Transcriptional activation inhibitory protein |
| US6511799B1 (en) | 1999-05-14 | 2003-01-28 | The Johns Hopkins University | CDX2 is downstream mediator of APC tumor suppressor activity |
| AU6944100A (en) * | 1999-09-01 | 2001-03-26 | Johns Hopkins University, The | Beta-catenin, tcf-4, and apc interact to prevent cancer |
| DE60017453T2 (de) * | 1999-11-26 | 2005-12-22 | Takeda Pharmaceutical Co. Ltd. | Transkriptionsfaktor und dessen dna |
| AU783128B2 (en) * | 2000-03-02 | 2005-09-29 | Innovata Plc | TCF responsive element |
| US6271257B1 (en) * | 2000-04-17 | 2001-08-07 | Hormos Nutraceutical Oy Ltd. | Decreasing the intracellular level of β-catenin by administering hydroxymatairesinol |
| US6787321B1 (en) * | 2000-10-13 | 2004-09-07 | The Regents Of The University Of California | Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products |
| WO2002044378A2 (en) * | 2000-11-28 | 2002-06-06 | Curis, Inc. | Wnt signalling assay, methods and uses thereof |
| EP1531842A4 (de) * | 2000-12-22 | 2007-03-07 | Dana Farber Cancer Inst Inc | Regulation des zellwachstums durch muc1 |
| US20030064384A1 (en) * | 2001-04-02 | 2003-04-03 | Mien-Chie Hung | Beta-catenin is a strong and independent prognostic factor for cancer |
| EP1385994A2 (de) * | 2001-04-02 | 2004-02-04 | Bayer HealthCare AG | Verfahren zur spezifischen detektion, isolation und charakterisierung von zellen aus körperproben durch transfektion von nukleinsäurekonstrukten |
| AU2002361654A1 (en) * | 2001-12-13 | 2003-06-30 | Exelixis, Inc. | Mbcats as modifiers of the beta-catenin pathway and methods of use |
| US7005293B2 (en) | 2001-12-18 | 2006-02-28 | Agilent Technologies, Inc. | Multiple axis printhead adjuster for non-contact fluid deposition devices |
| US20030187873A1 (en) * | 2002-04-02 | 2003-10-02 | Daniel Paffe | Secure paperless method and apparatus for managing a forensic chain of custody |
| US20040177813A1 (en) * | 2003-03-12 | 2004-09-16 | Applied Materials, Inc. | Substrate support lift mechanism |
| US20050019914A1 (en) * | 2003-07-24 | 2005-01-27 | Aventis Pharma Deutschland Gmbh | Perfusion process for producing erythropoietin |
| JP2010510236A (ja) | 2006-11-15 | 2010-04-02 | ダナ−ファーバー キャンサー インスティテュート インク． | 安定化させたｍａｍｌペプチドおよびその使用法 |
| AU2010204648B2 (en) | 2009-01-14 | 2016-09-01 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| AU2010298338A1 (en) * | 2009-09-22 | 2012-04-12 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| WO2017004548A1 (en) | 2015-07-01 | 2017-01-05 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| EP3555627B1 (de) | 2016-12-14 | 2023-11-22 | Purdue Research Foundation | Auf fibroblastenaktivierungsprotein (fap) gerichtete bildgebung und therapie |
-
1997
- 1997-03-20 US US08/821,355 patent/US5851775A/en not_active Expired - Lifetime
-
1998
- 1998-01-07 US US09/003,687 patent/US5998600A/en not_active Expired - Lifetime
- 1998-03-20 EP EP98912994A patent/EP0972037B1/de not_active Expired - Lifetime
- 1998-03-20 AU AU67658/98A patent/AU6765898A/en not_active Abandoned
- 1998-03-20 AT AT98912994T patent/ATE336575T1/de active
- 1998-03-20 WO PCT/US1998/005506 patent/WO1998041631A2/en active IP Right Grant
- 1998-03-20 DE DE69835590T patent/DE69835590T2/de not_active Expired - Lifetime
- 1998-03-20 CA CA2285701A patent/CA2285701C/en not_active Expired - Lifetime
- 1998-03-20 JP JP54083298A patent/JP2001522234A/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998041631A3 (en) | 1998-12-03 |
| DE69835590T2 (de) | 2007-08-16 |
| AU6765898A (en) | 1998-10-12 |
| US5851775A (en) | 1998-12-22 |
| EP0972037A2 (de) | 2000-01-19 |
| US5998600A (en) | 1999-12-07 |
| WO1998041631A2 (en) | 1998-09-24 |
| EP0972037B1 (de) | 2006-08-16 |
| CA2285701C (en) | 2013-09-17 |
| DE69835590D1 (de) | 2006-09-28 |
| JP2001522234A (ja) | 2001-11-13 |
| CA2285701A1 (en) | 1998-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE336575T1 (de) | Die interaktion von beta-catenin, tcf-4 und apc führt zur verhütung von krebs | |
| Cordon-Cardo et al. | At the crossroads of inflammation and tumorigenesis | |
| CA2282812A1 (en) | Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof | |
| Bálint et al. | Mdm2 binds p73α without targeting degradation | |
| Gimm et al. | Expression of the PTEN tumour suppressor protein during human development | |
| Hou et al. | The histone deacetylase inhibitor trichostatin A derepresses the telomerase reverse transcriptase (hTERT) gene in human cells | |
| Nylander et al. | Characterization of the expression pattern of p63α and ΔNp63α in benign and malignant oral epithelial lesions | |
| AU2853395A (en) | Recombinant vectors derived from adenovirus for use in gene therapy | |
| WO1998039467A3 (en) | Adenovirus vectors specific for cells expressing carcinoembryonic antigen and methods of use thereof | |
| WO1998039465A3 (en) | Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof | |
| Miyoshi et al. | β-Catenin: a transforming actor on many stages | |
| Nouman et al. | The role of the tumour suppressor p33ING1b in human neoplasia | |
| CA2217668A1 (en) | Genetic markers for breast and ovarian cancer | |
| WO1995011984A3 (en) | Recombinant adenoviral vector and methods of use | |
| AU7688991A (en) | Compositions and methods for synthesizing ladle slags, treating ladle slags, and coating refractory linings | |
| CY1111931T1 (el) | Φορεις αδενοϊων για την αγωγη νοσου | |
| AU6618696A (en) | P53 protein variants and therapeutical uses thereof | |
| ATE267868T1 (de) | C-myc wird aktiviert durch beta-catenin und tcf-4 | |
| WO1998004709A3 (en) | Herpes simplex virus ICP4 is an inhibitor of apoptosis | |
| Navone et al. | TabBO: a model reflecting common molecular features of androgen-independent prostate cancer | |
| WO2005007193A3 (en) | Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor | |
| Ozen et al. | Structural alterations of chromosome 5 in twelve human prostate cancer cell lines | |
| WO2001002540A3 (en) | Adenoviral vectors for treating disease | |
| CA2067797A1 (en) | Production and use of human nm23 protein and antibodies therefor | |
| Man et al. | Allelic losses at 3p and 11p are detected in both epithelial and stromal components of cervical small-cell neuroendocrine carcinoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0972037 Country of ref document: EP |